Ankyra Medical Journal (AnkMJ), formerly known as the Journal of Translational and Practical Medicine, regularly publishes international quality issues in the field of Medicine in the light of current information.

EndNote Style
Original Article
Evaluation of serum natural antioxidant levels in patients with schizophrenia, schizoaffective disorder, and bipolar disorder
Aims: Evidence for the role of oxidative stress in psychiatric disorders is growing. This study aimed to evaluate laboratory parameters related to oxidative stress, such as uric acid, albumin, and total bilirubin, which can be easily measured in serum in patients with schizophrenia, schizoaffective disorder, and bipolar disorder, and to compare them with healthy controls.
Methods: The study included 221 patients diagnosed with schizophrenia, schizoaffective disorder, and bipolar disorder according to DSM-5 criteria and 104 healthy individuals. The patient and control groups were compared in terms of serum uric acid, albumin, and total bilirubin values.
Results: A statistically significant difference was in uric acid levels among the schizophrenia group, schizoaffective disorder, bipolar disorder, and the control group (p<0.001 for all). Similarly, significant differences were identified between the patient groups and the control group in terms of albumin levels (p= 0.002, p<0.001, p<0.001, p<0.001, respectively). Total bilirubin levels also exhibited significant differences between schizophrenia and schizoaffective disorder, schizoaffective disorder and control group, and bipolar disorder and the control group (p<0.04, p= 0.007, p= 0.044, respectively).
Conclusion: Patients differed from controls in terms of serum natural antioxidants. The findings in our study support a causal relationship between schizophrenia, schizoaffective disorder, and bipolar disorder and uric acid, albumin, and total bilirubin.

1. Brown NC, Andreazza AC, Young LT. An updated meta-analysis ofoxidative stress markers in bipolar disorder. Psychiatry Res. 2014;218(1-2):61-68.
2. Guidara W, Messedi M, Naifar M, et al. Predictive value of oxidativestress biomarkers in drug free patients with schizophrenia and schizo-affective disorder. Psychiatry Res. 2020;293:113467.
3. Pizzino G, Irrera N, Cucinotta M, et al. Oxidative stress: harms andbenefits for human health. Oxid Med Cell Longev. 2017;2017:8416763.
4. Sies H. Oxidative stress: from basic research to clinical application. AmJ Med. 1991;91(3C):31S-38S.
5. Atlan N, Sepici Din&ccedil;el A, Koca C. Diabetes mellitus and oxidativestress. Turk J Biochem. 2006;31(2):51-56.
6. Bulbul F, Virit O, Alpak G, et al. Are oxidative stress markers usefulto distinguish schizoaffective disorder from schizophrenia and bipolardisorder? Acta Neuropsychiatr. 2014;26(2):120-124.
7. Şahin Ş, Aybastı &Ouml;, Elboğa G, Altındağ A, Tamam L. Effect ofelectroconvulsive therapy on oxidative metabolism in major depressivedisorder. Cukurova Med J. 2017;42(3):513-517.
8. Chen S, Xia HS, Zhu F, et al. Association between decreasedserum albumin levels and depressive symptoms in patients withschizophrenia in a Chinese Han population: a pilot study. PsychiatryRes. 2018;270:438-442.
9. Kazgan Kılı&ccedil;aslan A, Yıldız S, Kurt O, Korkmaz S. Serum uric acidlevels in schizoaffective disorder. Bosphorus Med J. 2022; 9(2):93-101.
10. Kumar AN, Aruna P, Naidu JN, Kumar R, Srivastava AK. Review ofconcepts and controversies of uric acid as antioxidant and pro-oxidant.Arch Med Rev J. 2015;24(1):19-40.
11. Jinnah HA. Lesch-Nyhan disease: from mechanism to model and backagain. Dis Model Mech. 2009;2(3-4):116-121.
12. Bartoli F, Burnstock G, Crocamo C, Carr&agrave; G. Purinergic signaling andrelated biomarkers in depression. Brain Sci. 2020;10(3):160.
13. Yao JK, Dougherty GG Jr, Reddy RD, et al. Homeostatic imbalanceof purine catabolism in first-episode neuroleptic-na&iuml;ve patients withschizophrenia. PLoS One. 2010;5(3):e9508.
14. Mabrouk H, Houas I, Mechria H, et al. Oxidative stress markersin schizophrenic patients. Immuno-analyse Biolog Sp&eacute;cialis&eacute;e.2013;28(1):51-56.
15. He Q, You Y, Yu L, et al. Uric acid levels in subjects with schizophrenia:a systematic review and meta-analysis. Psychiatry Res. 2020;292:113305.
16. Reddy R, Keshavan M, Yao JK. Reduced plasma antioxidants in first-episode patients with schizophrenia. Schizophr Res. 2003;62(3):205-212.
17. Luo Q, Wen Z, Li Y, et al. Assessment causality in associations betweenserum uric acid and risk of schizophrenia: a two-sample bidirectionalmendelian randomization study. Clin Epidemiol. 2020;12:223-233.
18. Bartoli F, Crocamo C, Mazza MG, Clerici M, Carr&agrave; G. Uric acid levelsin subjects with bipolar disorder: a comparative meta-analysis. JPsychiatr Res. 2016;81:133-139.
19. Albert U, De Cori D, Aguglia A, Barbaro F, Bogetto F, Maina G.Increased uric acid levels in bipolar disorder subjects during differentphases of illness. J Affect Disord. 2015;173:170-175.
20. Kesebir S, Tatlıdil Yaylacı E, S&uuml;ner O, G&uuml;ltekin BK. Uric acid levelsmay be a biological marker for the differentiation of unipolar andbipolar disorder: the role of affective temperament. J Affect Disord.2014;165:131-134.
21. Belinskaia DA, Voronina PA, Shmurak VI, et al. The universal soldier:enzymatic and non-enzymatic antioxidant functions of serum albumin.Antioxidants. 2020;9(10):966.
22. Zhai D, Liu Y, Ma F, et al. Effects of the first exposure of antipsychoticson serum albumin in adolescents and young adults with first-episodeschizophrenia. J Clin Psychopharmacol. 2018;38(1):103-105.
23. Huang TL. Lower serum albumin levels in patients with mooddisorders. Chang Gung Med J. 2002;25(8):509-513.
24. Pae CU, Paik IH, Lee C, Lee SJ, Kim JJ, Lee CU. Decreased plasmaantioxidants in schizophrenia. Neuropsychobiol. 2004;50(1):54-56.
25. Radhakrishnan R, Kanigere M, Menon J, Calvin S, Janish A, SrinivasanK. Association between unconjugated bilirubin and schizophrenia.Psychiatry Res. 2011;189(3):480-482.
Volume 3, Issue 2, 2024
Page : 41-45